Milsaperidone (VHX-896) vs Olanzapine (Zyprexa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT03510325 · Phase 3 · completed
This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)
Result source: NCT03510325
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Olanzapine (Zyprexa) |
|---|---|---|
| PANSS total, change | —Not reported | -8.8 vs 4.5−13.3 vs placeboNCT00686998 |
| CGI-S, change | —Not reported | —Not posted · NCT00083668 |
| PANSS response | —Not reported | 31.7% vs 44.7%avs amisulprideNCT03510325 |
| PSP, change | —Not reported | —Not posted · NCT00083668 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00083668 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Olanzapine (Zyprexa)
- -8.8 vs 4.5−13.3 vs placeboNCT00686998
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Olanzapine (Zyprexa)
- 31.7% vs 44.7%avs amisulprideNCT03510325
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Olanzapine (Zyprexa): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa) |
|---|---|
| Dropout rate | 63.4%Olanzapine/Intense Behavioral Weiga NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 38.2% NCT00190749 · Phase 4 · registry result, not featured evidence 60.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence 22%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 34.2%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 31.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 14.9%Olanzapine/Intense Behavioral Weiga NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 0% NCT00190749 · Phase 4 · registry result, not featured evidence 8.3% NCT00088465 · Phase 3 · registry result, not featured evidence — NCT00797277 · Phase 3 · registry result, not featured evidence 4%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 10.5%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 5.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 4.5% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Serious AEs | 19.8%Olanzapine/Intense Behavioral Weiga NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT00190749 · Phase 4 · registry result, not featured evidence 18.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence —Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence —Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination —Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 0% NCT00686998 · Phase 2 · registry result, not featured evidence 0%Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence 3.2%Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence 0%Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence 0%3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 25%0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 5.9%Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more resultsweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination weight increased 16.2% headache 10.3% sedation 10.3% NCT00190749 · Phase 4 · registry result, not featured evidence weight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence insomnia 10% somnolence 8% increased appetite 6% NCT00401973 · Phase 3 · registry result, not featured evidence somnolence 6.6% dry mouth 5.3% insomnia 5.3% NCT00401973 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.7% somnolence 11% nausea 6.8% NCT00401973 · Phase 3 · registry result, not featured evidence · combination weight increased 40.9% (placebo 0%) increased appetite 18.2% (placebo 2.4%) somnolence 18.2% (placebo 2.4%) NCT00686998 · Phase 2 · registry result, not featured evidence injection site irritation 6.9% injection site pain 6.9% psychotic disorder 6.9% NCT06319170 · Phase 1 · registry result, not featured evidence injection site pain 9.7% somnolence 9.7% blood creatine phosphokinase increased 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence alanine aminotransferase increased 6.5% aspartate aminotransferase increased 6.5% somnolence 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence 3 mg abnormal lab values 33.3% decreased appetite 16.7% depression 16.7% NCT00512070 · Phase na · registry result, not featured evidence · combination 0.3 mg abnormal lab values 50% depression 25% psychotic symptoms 25% NCT00512070 · Phase na · registry result, not featured evidence · combination abnormal lab values 29.4% insomnia/sleep disturbance 23.5% diarrhea 17.6% NCT00512070 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa)
show 3 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
+ 16 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa)
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Available safety results
Olanzapine (Zyprexa)
| Dropout rate | 63.4%Olanzapine/Intense Behavioral Weig NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more result55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | 14.9%Olanzapine/Intense Behavioral Weig NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more result18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
| Serious AEs | 19.8%Olanzapine/Intense Behavioral Weig NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more result12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
| Most frequent reported AEs | somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more resultweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Olanzapine (Zyprexa)'s landscape